MA-TA
28.6.2022 15:15:13 CEST | Business Wire | Press release
TA, a leading global growth private equity firm with more than four decades of enterprise software investing experience, in partnership with ST6, an elite team of software operating executives, has formed a global software provider called Advantive. The new company offers Enterprise Resource Planning (ERP), Manufacturing Execution Systems (MES), and Statistical Process Control (SPC) software solutions for specialty manufacturers and wholesale distributors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005803/en/
Advantive, which comes together through the combination of Advantzware, DDI System, Distribution One, InfinityQS, Kiwiplan and VIA, has more than 2,500 customers today across a number of industries including corrugated and packaging manufacturing, equipment and supply wholesale distributors, and automotive and other specialty manufacturers. Advantive will be headquartered in Tampa, Florida.
Benoit de la Tour, an accomplished executive in the ERP and Supply Chain software space, has been named the CEO of Advantive. “I'm thrilled to join Advantive as CEO, working hand-in-hand with TA and ST6 to deliver increased customer value,” said Benoit. “Advantive was formed with a simple purpose— to drive sustainable growth for specialty manufacturing and distribution companies. We’re in a unique position, alongside our customers, to make a real impact. With Advantive’s packaging, ecommerce and delivery solutions, spanning raw resources to valuable products, we’re transforming the manufacturing and distribution lifecycle.”
“We are excited to partner with Benoit and ST6 as we build upon the strength of Advantive’s constituent businesses to create an overall market leader in ERP, MES and SPC software,” said Hythem El-Nazer, a Managing Director at TA. “Advantive’s software solutions modernize and optimize every aspect of the manufacturing and distribution lifecycle, from enhanced plant production, supply chain optimization and ecommerce, to managing quality and compliance. Advantive is changing the way business is done, and we are excited to support the business as it grows.”
Mark Friedman, a longtime, experienced software operating executive and investor, is the Executive Chairman of Advantive. Friedman, currently a Managing Director at ST6, was previously the founder and CEO of Accruent, a leading software company that disrupted the multi-billion-dollar facilities management and lease administration software market. “Now more than ever, our customers need the ability to rapidly adapt to global supply chain challenges, and to gain a competitive advantage,” said Friedman. “By combining the strengths of Advantive’s constituent companies, and delivering deep, purpose-built software, we believe we are positioned to drive transformational outcomes for our customers.’
About Advantive
Advantive is a market leader in mission-critical software for specialty manufacturing and distribution companies, offering purpose-built ERP, MES and SPC software solutions that meet the unique needs of our customers. Serving over 2,500 customers and operating in 8 countries, Advantive’s software solutions streamline complex processes, optimize operations visibility and throughput, and drive improved quality, profitability and revenue growth. Deeply embedded into key end-to-end workflows, Advantive’s software uses automation, seamless integration and real-time data to streamline plant scheduling, order management, quality control, sales order forecasting and pricing, ecommerce and delivery – making the complex, simple.
About TA
TA is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer, and business services – the firm invests in profitable, growing companies with opportunities for sustained growth and has invested in more than 550 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $47.5 billion in capital since its founding in 1968. The firm’s more than 100 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com .
About ST6
ST6 is an elite team of software operating executives that partner with private equity sponsors to transform software companies and accelerate value creation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220628005803/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom